James M. Eudicone, MS, MBA
Articles
April 8th 2019
Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”
Eric T. Wittbrodt, PharmD, MPH James M. Eudicone, MS, MBA Kelly F. Bell, PharmD, MSPhr Devin M. Enhoffer, PharmD Keith Latham, PharmD Jennifer B. Green, MD
The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.
December 22nd 2011
Adjunctive Aripiprazole for Depression: Predictive Value of Early Assessment
David J. Muzina, MD Jessie S. Chambers, PhD Trixia A. Camacho, PharmD James M. Eudicone, MS, MBA Robert A. Forbes, PhD Robert M. Berman, MD Ross A. Baker, PhD
In treatment of depression with adjunctive aripiprazole, early improvement (week 2) was a significant predictor of remission, and lack of improvement was associated with nonremission.
